IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
14 févr. 2023 19h41 HE
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal...
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
14 févr. 2023 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment, respectively Data & Safety Monitoring Board...
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
31 janv. 2023 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
30 janv. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Barrow Women’s Board reaches milestone of $100M raised through Barrow Grand Ball
27 janv. 2023 17h07 HE
|
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
PHOENIX, Jan. 27, 2023 (GLOBE NEWSWIRE) -- PHOENIX, Ariz. (January 26, 2023) – The Women’s Board of Barrow Neurological Foundation netted over $7 million for Barrow Neurological Institute through...
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
25 janv. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
25 janv. 2023 04h00 HE
|
AKAMPION
- Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated...
AI in Medical Imaging Market is projected to Reach US$ 20.9 Billion by 2030, at a CAGR of 36.87% during the forecast period 2023-2030, Contrive Datum Insights
25 janv. 2023 00h00 HE
|
Contrive Datum Insights Pvt Ltd
Farmington, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The global AI in Medical Imaging Market was valued at USD 1.7 Billion in 2022 and is projected to reach USD 20.9 Billion by 2030, growing at a CAGR of...
Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
24 janv. 2023 12h12 HE
|
Trethera Corporation
LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board
13 janv. 2023 09h00 HE
|
Neurocentria, Inc
WALNUT CREEK, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Neurocentria, Inc., a privately held late-stage biotechnology company developing novel therapies for neurodegenerative and neuropsychiatric...